- Home
- GCI vs KALV Comparison
GCI vs KALV Comparison
Compare GCI & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCI
- KALV
- Stock Information
- Founded
- GCI 1997
- KALV N/A
- Country
- GCI United States
- KALV United States
- Employees
- GCI N/A
- KALV N/A
- Industry
- GCI Newspapers/Magazines
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- GCI Consumer Discretionary
- KALV Health Care
- Exchange
- GCI Nasdaq
- KALV Nasdaq
- Market Cap
- GCI 621.7M
- KALV 551.2M
- IPO Year
- GCI N/A
- KALV N/A
- Fundamental
- Price
- GCI $4.55
- KALV $13.41
- Analyst Decision
- GCI Buy
- KALV Strong Buy
- Analyst Count
- GCI 3
- KALV 8
- Target Price
- GCI $5.70
- KALV $26.43
- AVG Volume (30 Days)
- GCI 3.1M
- KALV 1.4M
- Earning Date
- GCI 10-30-2025
- KALV 11-10-2025
- Dividend Yield
- GCI N/A
- KALV N/A
- EPS Growth
- GCI N/A
- KALV N/A
- EPS
- GCI 0.59
- KALV N/A
- Revenue
- GCI $2,338,505,000.00
- KALV $1,426,000.00
- Revenue This Year
- GCI N/A
- KALV N/A
- Revenue Next Year
- GCI N/A
- KALV $234.65
- P/E Ratio
- GCI $7.65
- KALV N/A
- Revenue Growth
- GCI N/A
- KALV N/A
- 52 Week Low
- GCI $2.55
- KALV $7.30
- 52 Week High
- GCI $5.69
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- GCI 49.42
- KALV 57.38
- Support Level
- GCI $4.96
- KALV $10.55
- Resistance Level
- GCI $5.29
- KALV $14.97
- Average True Range (ATR)
- GCI 0.34
- KALV 0.87
- MACD
- GCI -0.04
- KALV 0.22
- Stochastic Oscillator
- GCI 44.02
- KALV 60.75
About GCI Gannett Co. Inc.
Gannett Co Inc is a digital newspaper company providing local media and marketing solutions in the U.S. The group operates in three segments, Domestic Gannett Media, Newsquest, and Digital Marketing Solutions. The majority of revenue is from the Domestic Gannett Media segment. The company's brands include USA TODAY and more than 250 daily newspapers as well as digital marketing services companies, including ReachLocal, WordStream, and others. The company produces more than 350 annual events, such as themed expos. The company also operates in the U.K. through the U.K. media company Newsquest, providing more than 150 local media brands.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.